NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

CDT Equity Inc. (CDT) Stock Analysis

CDT Equity Inc. (CDT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CDT

$0.63

−$0.12 (−16.56%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CDT with… →

CDT Key Statistics

As of Sep 4, 2026
Trading
Open
$0.73
Previous Close
$0.75
Day's Range
0.61–0.75
52-Week Range
0.61–2,440.00
Volume
728.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.45
Valuation
Market Cap
$8.56M
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$39.22M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
13.69M
1-Year Return
−99.74%
Dividend and dates
Avg Volume
736.06K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CDT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−98.05%
2025−99.85%
2024−98.48%
2023−55.61%
2022 (partial year)+3.12%

As of September 4, 2026.

CDT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$39.22M—
2024$0.00−$17.80M—
2023$0.00−$535.00K—
2022$0.00−$4.89M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$36.66M−$39.22M—
2024$0.00—−$15.11M−$17.80M—
2023$0.00—−$5.26M−$535.00K—
2022$0.00—−$3.16M−$4.89M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CDT Valuation vs Biotechnology Median

Median of 656 stocks
MetricCDTBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

CDT Equity Inc. (CDT) is capitalised at $8.56M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 4 employees.

CDT last closed at $0.63 on September 4, 2026. That is −$0.12 (−16.56%) against the previous close. The 52-week range on file runs from $0.61 to $2,440.00. The latest close sits 2.12% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $39.22M. The reported profit margin is 0%.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The trailing one-year price return is −99.74%. Across 3 years the annualized return works out at −99.42%. The reported beta is 1.45. Daily returns over the trailing 4 years annualize to a volatility of 545.17%.

Growth & Income

The record shows no dividend for CDT.

2026 is still running; the price is −98.05% year to date. The strongest complete calendar year on file is 2023 at −55.61%; the weakest is 2025 at −99.85%. Of the 3 complete calendar years on file, 0 finished higher.

Peer Comparison

CDT Equity Inc. (CDT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
CDT Equity Inc. CDT $8.56M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. CDT Equity Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About CDT Equity Inc.

CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.

Visit website →